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Abstract 
Recent trends in use of antihypertensive drugs are unknown. From Danish nationwide 
prescription data, we obtained information on primary care use of angiotensin 
converting enzyme inhibitors, angiotensin II receptor blockers, beta blockers, diuretics, 
aldosterone receptor antagonists and calcium channel blockers. During 1999–2015, the 
use of antihypertensive drugs per 1,000 inhabitants/day increased from 184 to 379 
defined daily doses (DDD), corresponding to a rise in the prevalence proportion of users 
from ≈20% to ≈35%. From 1999 to 2015, a notable increase was observed for 
angiotensin converting enzyme inhibitors (from 29 to 105 DDD per 1,000 
inhabitants/day ≈260%) and angiotensin II receptor blockers (from 13 to 73 DDD per 
1,000 inhabitants/day ≈520%). For diuretics the use remained stable, with a slight 
decrease (from 89 to 81 DDD per 1,000 inhabitants/day ≈-10%). The use of aldosterone 
receptor antagonists increased until 2007 and remained unchanged at around 3.5 DDD 
per 1,000 inhabitants/day thereafter (average change ≈65%). The use of beta blockers 
doubled during the study period (from 17 to 34 DDD per 1,000 inhabitants/day ≈100%), 
entirely driven by increasing use of metoprolol. Similar trends were observed for 
calcium channel blockers (from 34 to 82 DDD per 1,000 inhabitants/day ≈140%), 
where amlodipine drove the overall increase. In conclusion, antihypertensive drug use 
has increased remarkably during the past two decades. 
 
Key words: Antihypertensive drugs, trends, epidemiology
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Introduction 
During the past two decades, several important trials on antihypertensive drugs have 
emerged, which has led to changes in treatment recommendations such as the JNC 8.
1
 
Barriers to implementation of international guidelines can arise at different levels such 
as national, regional, institutional, and individual provider level. The implementation of 
guideline recommendations in clinical practice is unclear and nationwide trends in use 
of antihypertensive drugs can provide important insight into how rapidly results from 
clinical trials and guidelines are adopted in clinical practice. The objective of this study 
was to examine 17-year trends in use of antihypertensive drugs in Denmark and provide 
a discussion of their temporal relationship with landmark studies. 
 
Methods 
The study was conducted in Denmark from 1 January 1999 to 31 December 2015. 
Denmark has a population of approximately 5.7 million inhabitants, who all have free 
and unfettered access to tax-supported healthcare at general practitioners and hospitals. 
Partial reimbursement for prescribed medications, including antihypertensive drugs, is 
also covered by taxes. Antihypertensive drug sales in Danish community pharmacies 
comprise purchases of prescription drugs, including prescriptions to in- and outpatients 
at discharge from hospitals. 
 MEDical STATistics (Medstat) is a publicly accessible database providing data 
on drug use in the Danish primary sector since 1996, divided by age and sex from 1999 
onwards and hospital sector since 1997.
2
 We retrieved data on use of antihypertensive 
drugs according to the Anatomical Therapeutic Chemical (ATC) classification system 
from Medstat. Data registered in Medstat include drug sale in defined daily doses 
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(DDD). The DDD is a WHO-defined measure of drug consumption representing the 
assumed average maintenance dose required by an adult when the drug is used for its 
main indication. Reporting data as DDD allows for comparison of trends in drug 
utilization independent of varying prices and pack sizes. Changes in WHO-defined 
DDD for each drug are incorporated into Medstat updates each year allowing for 
comparison of drug use over time.
2
 As the actual denominator used in the calculations 
of the prevalence of users is not provided directly in Medstat, we obtained information 
on the size of the Danish population during 1999 to 2015 according to age groups and 
sex from Statistics Denmark.
3
 According to Danish law, no approval from an ethical 
committee was required for this study. 
 We identified use of angiotensin converting enzyme (ACE) inhibitors, angiotensin 
II receptor blockers (ARBs), diuretics, aldosterone receptor antagonists (ARAs), beta 
blockers, and calcium channel blockers (CCBs). Specific ATC codes and drugs within 
these main classes of antihypertensive drugs are specified in Supplemental Table 1. 
 We compiled data from dispensed prescriptions of antihypertensive drugs in DDD 
per 1,000 inhabitants/day from Danish community pharmacies and the number of 
antihypertensive drug users per 1,000 inhabitants. We stratified drug use by sex, age 
groups (20-39 years, 40-64 years, 64-80 years, and >80 years), age groups separately 
for men and women, and administrative regions (Capital Region of Denmark, North 
Denmark Region, Central Denmark region, Region Zealand, and Region of Southern 
Denmark, available since 2007). Additionally, we retrived information on in-hospital 
use of antihypertensive drugs during 1999‒2015. 
 To identify clinical trials that may have influenced the trends in use of 
antihypertensive drugs, we performed a systematic search in MEDLINE (Pubmed) in 
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collaboration with a qualified research librarian. The search included terms for specific 
antihypertensive drug classes, indications for their use, and was restricted to clinical 
trials within the study period (full search string available in the Supplemental Material). 
The search returned 1248 hits from which JS identified 22 landmark trials by screening 
abstracts supplemented by a review of references of included studies (Figure 1). In 
addition to trials on hypertensive populations, we included heart failure trials as all the 
studied antihypertensive drugs (apart from CCBs) are used in heart failure treatment and 
hence influence the utilisation trends. 
 
Results 
From 1999 to 2015, the overall use of antihypertensive drugs per 1,000 inhabitants 
increased from 184 DDD to 379 DDD (Table 1 and Figure 1). In addition, the 
prevalence of antihypertensive drug users increased from ≈20% to ≈35% of the entire 
Danish population (Table 1). During 1999–2015, the number of Danish inhabitants 
remained relatively unchanged and the age- and sex distribution did not change 
substantially (Supplemental Table 2). 
 During the study period, the use of ACE inhibitors increased more than 3-fold and 
the use of ARBs more than 5-fold (Table 1). Diuretics decreased only slightly, while the 
use of beta blockers doubled and the use of CCBs more than doubled. In-hospital use of 
antihypertensive drugs constituted a negligible fraction of the total use (3 DDD per 
1,000 inhabitants/day in 2015), and the use decreased during the 17-year study period 
(Supplemental Table 3). Although small regional differences were observed, the use of 
antihypertensive drugs in individual administrative regions of Denmark was consistent 
with the national trends (Supplemental Table 4).  
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 ACE inhibitors were the most frequently used antihypertensive drug (Table 1). 
For ramipril, enalapril, and combination drugs (ACE inhibitors and diuretics), the use 
increased markedly over time until 2010 when they declined slightly (Figure 2). The use 
of other ACE inhibitors was low throughout the study period. More men than women 
used ACE inhibitors and the use was most frequent in age categories above 65 years 
(Figure 3). 
 The overall use of ARBs increased slightly until 2009, after which only the use of 
losartan increased dramatically (Figure 2). Use of combination pills with ARBs and 
diuretics increased more steadily throughout the study period. The remaining ARBs 
increased similarly until 2009 but then dropped abruptly to remain close to zero from 
2011 onwards. Slightly more women than men used ARBs and the use was most 
frequent in age categories above 65 years (Figure 3). 
 The use of diuretics peaked around 2007, succeeded by a moderate decrease 
through 2015 (Figure 2). The most frequently used diuretics were furosemide and 
combination pills with thiazides and potassium. The use of thiazides without potassium 
was low and ceased completely after 2010. The use of bumetanide was consistently low. 
More women than men used diuretics and the use increased proportionally with 
advancing age category (Figure 3). 
 The use of spironolactone increased abruptly from 1999–2001, whereafter the use 
was consistent (around 3.5 DDD per 1,000 inhabitants/day). Similarly, the use of 
eplerenone increased after its 2004 introduction and became stable two years thereafter 
at around 0.1 DDD per 1,000 inhabitants/day. More women than men used ARAs and 
the use increased proportionally with increasing age (Figure 3).  
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 The use of metoprolol increased substantially over the study period (from 6.7 
DDD per 1,000 inhabitants/day in 1999 to 22.7 in 2015). The use of the remaining beta 
blockers was below 5 DDD per 1,000 inhabitants/day and decreasing for atenolol and 
sotalol, while carvedilol increased slightly. Overall use was the same for men and 
women and most frequently used in those above 65 years of age (Figure 3). 
  Throughout the study period the use of amlodipine increased consistently from 18 
DDD per 1,000 inhabitants/day in 1999 to reach 72 in 2015. The use of the remaining 
CCBs (felodipin, nifedipin, verapamil, and diltiazem) was low and decreased slightly 
during the study period. Use of CCBs showed an equal sex distribution in 1999, but 
over time, the use increased relatively more for men than for women (Figure 3). The use 
of CCBs was most frequent in those above 65 years of age (Figure 3). 
 For all classes of antihypertensive drugs, the age-stratified analyses among men 
and women separately (Supplemental Figure 1) were in accordance with the overall 
age-stratified analysis (Figure 3). 
 
Discussion 
During the past 17 years, the use of antihypertensive drugs in Denmark has more than 
doubled. In particular, ramipril and enalapril were the most commonly used ACE 
inhibitors, and losartan, amlodipin and metoprolol by far the most used ARB, CCB, and 
beta blocker, respectively. A recent trend study from the US agreed overall with our 
findings, but no study has examined the profound changes we observed after 2010. 
 The overall trends are likely driven by recommendations in international clinical 
guidelines from European Societies of Cardiology and Hypertension
4-6
 and The Joint 
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National Committee in The United States,
1,7
 as well as major clinical trials. Below, we 
discuss the observed trends in the light of landmark studies. 
 The use of ACE inhibitors increased dramatically during the study period, driven 
by enalapril, ramipril, and combinations of ACE inhibitors and diuretics. The increase 
was likely fuled by the HOPE trial
8
 in 2000 showing that ramipril reduces the rates of 
death, myocardial infarction, and stroke in a broad range of high-risk patients who were 
not known to have a low ejection fraction or heart failure. The EUROPA trial in 2003 
further supported treatment with an ACE inhibitor in patients with stable coronary heart 
disease without apparent heart failure.
9
 The slight decrease observed for most ACE 
inhibitors after 2010 may be associated with the losartan patent expiration in 2009 
causing a shift to ARBs for patients with side effects to ACE inhibitors (e.g., cough). 
 During 1999–2010, the use of ARBs increased continuously and similarly for all 
ARBs. This steady increase may have been supported by the ValHeFT trial
10
 (2001) and 
the LIFE trial (2002),
11
 favoring use of valsartan and losartan, respectively. This was 
followed by results from the CHARM trials in 2003 demonstrating beneficial effect of 
candesartan on various outcomes and in various patient groups.
12-14
 The CHARM-
preserved trial,
15
 however, failed to demonstrate any significant reduction in 
cardiovascular death and heart failure hospitalization in patients with preserved (>40%) 
left ventricular ejection fraction. The most striking change in use of ARBs occurred 
after 2009 where the use of losartan surged while the use of candesartan and other 
ARBs correspondingly plummeted, presumably prompted by expiration of the losartan 
patent in 2009. Contributing to this surge in losartan use, the HEAAL study (2009) 
demonstrated that high-dose losartan (150 mg/day) in patients with heart failure reduced 
all-cause mortality and hospitalization for heart failure more effectively, as compared to 
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low-dose losartan (50 mg/day).
16
 Likewise, the ONTARGET trial confirmed ARBs as 
an equally effective alternative to ACE inhibitors and with a better safety profile.
17
 
 The use of diuretics decreased only slightly during the study period. The use of 
furosemide and thiazides in combination with potassium was most used. The high use 
of thiazides is likely supported by the ALLHAT trial published in 2002,
18
 
recommending thiazide-type diuretics as first-line drug for essential hypertension. The 
slight decrease in thiazide use in the last part of the study period could have been 
influenced by the ACCOMPLISH trial from 2008.
19
 The trial concluded that ACE 
inhibition in combination with amlodipine was superior in reducing adverse 
cardiovascular events compared with ACE inhibitors and thiazides. However, also in 
2008, the HYVET trial
20
 provided evidence that antihypertensive treatment with the 
thiazide indapamide reduces all-cause mortality in older patients. 
 The indication for ARA use is primarily congestive heart failure and 
hyperaldosteronism and to a much lesser extent hypertension. The RALES study
21
 
(1999) was the first of a series of trials to examine the effect of ARAs on mortality in 
patients with congestive heart failure and demonstrated a 30% reduction in all-cause 
mortality with spironolactone in a randomization of heart failure patients. The RALES 
trial prompted the subsequent EPHESUS trial
22
 (2003), which also supported 
eplerenone use for heart failure following myocardial infarction. The later EMPHASIS-
HF trial
23
 (2011) also supported the use of eplerenone in the treatment of moderate heart 
failure with mild symptoms.  
 Apart from metoprolol, beta blockers saw only minor changes in use throughout 
the study period. For metoprolol, the use increased continuously since 1999. Metoprolol 
is used for a broad range of cardiovascular diseases and the increasing use likely mirrors 
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an increase in the prevalence of these diseases during the study period.
24
 Moreover, in 
1999, the MERIT-HF trial
25
 (metoprolol) and CIBIS-II trial
26
 (bisoprolol) both 
demonstrated a 34% relative risk reduction in all-cause mortality in the treatment arm 
for heart failure patients with reduced ejection fraction. Carvedilol for heart failure was 
investigated in the COPERNICUS trial
27
 (2002) that randomized patients with severe 
heart failure to carvedilol or placebo and demonstrated a reduced risk of death or heart 
failure hospitalization by 31% compared with placebo. The MERIT-HF
25
 and 
COPERNICUS
27
 trials were followed by the COMET trial
28
 (2003) favouring the use of 
carvedilol over metoprolol (40% vs. 34% relative risk reduction for mortality). 
  The accelerated use of amlodipine after 2004 coincides with the publication of the 
VALUE trial in 2004.
29
 This trial demonstrated that in hypertensive patients, stroke and 
myocardial infarction incidence was lower in the amlodipine group than in the valsartan 
group. In 2005 the ASCOT-BPLA trial also identified amlodipine as most effective in 
preventing major cardiovascular events.
30
 The ACCOMPLISH trial (2008) further 
favored CCBs over thiazides in patients at high risk of cardiovascular complications.
19
 
 The nationwide coverage eliminated selection bias and the Medstat database is 
complete and data prospectively recorded.
2
 
 In conclusion, use of antihypertensive drugs more than doubled during the past 
two decades, driven by increased use of ramipril, enalapril, losartan, metoprolol, and 
amlodipine.  
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Figure legends 
 
Figure. 1. Timeline in use of antihypertensive drugs in Denmark and publication year of 
landmark studies, 1999−2015. 
Abbreviations: ACCOMPLISH: Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk 
Patients study; ALLHAT: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting 
enzyme inhibitor or calcium channel blocker vs diuretic study; ASCOT-BPLA: Prevention of cardiovascular events 
with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding 
bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm 
(ASCOT-BPLA): a multicentre randomised controlled trial; CHARM-Added: Effects of candesartan in patients with 
chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: 
the CHARM-Added trial; CHARM-Alternative: Effects of candesartan in patients with chronic heart failure and 
reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: CHARM-
Alternative trial; CHARM Low LVEF: Mortality and morbidity reduction with Candesartan in patients with chronic 
heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction 
trials; CHARM-preserved: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular 
ejection fraction: the CHARM-Preserved Trial; CIBIS-II: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): 
a randomised trial; COMET: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic 
heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial; 
COPERNICUS: Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure; ESH/ESC 
guideline: European Society of Hypertension guideline on hypertension; EMPHASIS-HF: Eplerenone in Patients 
with Systolic Heart Failure and Mild Symptoms study; EPHESUS: Eplerenone, a Selective Aldosterone Blocker, in 
Patients with Left Ventricular Dysfunction after Myocardial Infarction study; EUROPA: Efficacy of perindopril in 
reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, 
placebo-controlled, multicentre trial (the EUROPA study); HEAAL: Effects of high-dose versus low-dose losartan 
on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial; HOPE: Effects 
of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients study; 
HYVET: Treatment of Hypertension in Patients 80 Years of Age or Older study; JNC: Joint National Committee 
guideline on hypertension; LIFE: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint 
reduction in hypertension study; MERIT-HF: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol 
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CR/XL Randomised Intervention Trial in Congestive Heart Failure; ONTARGET: Telmisartan, Ramipril, or Both in 
Patients at High Risk for Vascular Events; RALES: The effect of spironolactone on morbidity and mortality in 
patients with severe heart failure study; ValHeFT: A randomized trial of the angiotensin-receptor blocker valsartan 
in chronic heart failure; VALUE: Outcomes in hypertensive patients at high cardiovascular risk treated with 
regimens based on valsartan or amlodipine study. 
 
Figure. 2. Use of angiotensin converting enzyme inhibitors (A), angiotensin II receptor blockers 
(B), diuretics (C), aldosterone receptor blockers (D), beta blockers (E), and calcium channel 
blockers (F) in defined daily doses per 1,000 inhabitants/day in the primary health care sector, 
1999‒2015.a 
a
Note the different scales on the y-axis. Other ACEIs include captopril, lisinopril, perindopril, quinapril, benazepril, 
fosinopril, trandolapril, moexipril, zofenopril, and ACEI/calcium channel blocker combinations. Other ARBs 
include valsartan, eprosartan, irbesartan, telmisartan, olmesartan, and ARB/calcium channel blocker combinations. 
Abbreviations: ACEI, angiotensin converting enzyme inhibitors; ARBs, angiotensin II receptor blockers. 
 
Fig. 3. Age- and sex-stratified primary care use of antihypertensive drugs in defined daily doses 
per 1,000 inhabitants/day, 1999–2015.a 
a
Note the different scales on the y-axis. Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin II 
receptor blockers; ARA, aldosterone receptor antagonists; CCB, calcium channel blockers.  
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Table I. Antihypertensive drug use in the primary health care sector during 1999‒2015 in Denmark.  
 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Overall                  
DDD
a
 184 194 208 225 244 266 285 307 328 348 362 375 373 378 381 380 379 
Users
b
 195 206 221 237 255 274 293 309 325 337 355 359 361 361 360 355 352 
ACE inhibitors                  
DDD
a
 29 32 36 42 48 55 62 71 78 88 101 109 110 111 110 107 105 
Users
b
 27 29 32 35 40 46 52 58 63 68 82 82 79 77 75 72 70 
ARBs                  
DDD
a
 12 14 17 22 27 31 34 39 44 49 47 49 53 59 64 67 72 
Users
b
 15 17 20 25 29 32 35 39 43 47 46 47 52 55 59 62 65 
Diuretics                  
DDD
a
 89 89 91 92 94 98 100 101 101 101 99 98 93 89 88 85 81 
Users
b
 76 78 81 82 86 90 93 94 94 93 92 92 88 85 82 78 75 
ARAs                  
DDD
a
 2.3 2.8 3.2 3.3 3.4 3.4 3.5 3.6 3.8 3.8 3.6 3.6 3.7 3.7 3.7 3.8 3.8 
Users
b
 4.71 6.31 7.17 7.63 7.79 7.93 8.34 8.51 8.56 8.56 8.52 8.49 8.61 8.77 9.1 9.25 9.5 
Beta blockers                  
DDD
a
 17 18 20 23 25 28 30 31 32 33 33 33 33 34 34 34 34 
Users
b
 36 40 44 48 52 56 59 61 63 64 64 65 66 67 67 67 67 
CCBs                  
DDD
a
 34 36 38 40 41 44 48 54 60 64 70 75 78 80 82 82 82 
Users
b
 36 37 38 39 40 42 45 49 53 57 62 65 67 68 68 67 67 
Abbreviations: ACE, angiotensin converting enzyme; ARBs, angiotensin II receptor blockers; ARA, aldosterone receptor blockers; CCBs, calcium channel blockers.  
a
Defined daily doses per 1,000 inhabitants/day  
b
Number of users per 1,000 inhabitants 
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